The recent publication of a comprehensive report analyzing the global market for pediatric combination vaccines, specifically those based on acellular pertussis (aP), offers valuable insights into the evolving landscape of immunization against infectious diseases in children.
This analysis focuses on hexavalent and pentavalent combination vaccines, which are critical tools in the fight against a multitude of diseases in early childhood.
Remarkably, the immunization rate experienced a rebound, with DTP3 coverage climbing to 84% in 2022, up from 81% in 2021. This increase is credited to various factors, including recovery from the COVID-19 pandemic, the integration of these vaccines into National Immunization Programs, and the shifting economic statuses of several countries.
%2c%202022.jpg?width=612&height=347&name=Sanofi.%20DTP3%20immunization%20rate%20(WHO%20Database)%2c%202022.jpg)
DTP3 immunization rate (WHO Database), 2022
Pediatric combination vaccines have transformed the approach to immunization, allowing for the administration of multiple vaccines in a single shot, thus improving vaccination rates and reducing the discomfort for the young recipients. The current study delves into the global volumes of aP-based hexavalent and pentavalent combination vaccines, revealing significant trends in their utilization across different regions, countries, and even down to specific brands, showcasing market dynamics and leadership.
The report underlines the pivotal role of certain indicators, such as immunization rates, the surviving infants' population, and immunization schedules, in driving the demand for these vaccines. The direct correlation between these indicators and the volumes of vaccines administered highlights the underlying factors influencing vaccine uptake globally.
A standout finding from the study is the market growth observed in the aP-based pediatric hexavalent and pentavalent combination vaccine segment. From 2021 to 2022, the hexavalent vaccine market experienced growth from 35.3 million doses to 37.5 million doses, whereas the pentavalent vaccine market saw a slight decline from 30.8 million to 30.5 million doses. This indicates nuanced shifts in vaccine preference and adoption across different markets.
Global DTP vaccine split, 2022
Sanofi emerges as a clear market leader, retaining a significant share of the market in 2022, with its Hexaxim® (hexavalent vaccine) and Pentaxim® (pentavalent vaccine) brands. The report’s detailed analysis of market shares and preferences underscores the competitive landscape and the varying degrees of market penetration achieved by different vaccine brands.
Global hexavalent vaccines volume, market share by manufacturer, 2022
The dynamics between public and private markets also play a crucial role in vaccine distribution, with government financing and immunization schedules predominantly driving public market demand. In contrast, vaccine availability and affordability are key drivers in private markets. The study's findings suggest a higher administration of aP-based combination vaccines in private markets compared to public markets in 2022, reflecting socioeconomic factors and healthcare infrastructure disparities.
Geographically, Europe stands out for its substantial share of the aP-based combination vaccines market, particularly in hexavalent and pentavalent vaccines. This regional analysis, along with the detailed breakdown of vaccine usage in the top countries, provides a clear picture of global vaccination strategies and their effectiveness.
Hexavalent vaccine volume analysis, by region, 2022
Sanofi's dominance in the market is further highlighted by the significant usage of its Hexaxim® and Pentaxim® vaccines, showcasing the trust and reliance placed in these brands by healthcare providers and recipients alike.
In conclusion, the latest report on pediatric combination vaccines provides a thorough analysis of the current state of the market, revealing trends, challenges, and opportunities. The data presented not only underscores the critical role of these vaccines in global public health strategies but also highlights the market dynamics shaping their distribution and adoption.
As we move forward, understanding these trends will be crucial in addressing the needs of the world's youngest and most vulnerable populations.
A White Paper To Understand The Market Structure Of Pediatric Pertussis Combination Vaccines Landscape (2022) contains rich insights on worldwide usage patterns for hexavalent and pentavalent vaccines, together with the volumes administered by brand.
Worldwide usage patterns and the volumes administered by brand across aP-based hexavalent, pentavalent and school entry booster vaccines.
Worldwide usage patterns and the volumes administered by brand across aP-based hexavalent, pentavalent and school entry booster vaccines.
ReportLinker’s Market Intelligence Platform provides market insights you need to build a sector profile, track its evolution, and evaluate its future.
